drugset
drugset / Trial / NCT04124653

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants

NCT04124653 ↗

Phase 1 Completed 44 enrolled Pfizer
RandomizedParallel-groupDouble-blindBasic science

Summary

This study will be the first time PF-06842874 is administered to humans. The purpose of Part A of the study is to investigate the safety, tolerability, and pharmacokinetics of PF-06842874 following administration of single oral doses as an immediate-release or modified-release formulation to healthy adult participants. Part B of this study will evaluate the relative bioavailability of a modified-release formulation of PF-06842874 for its potential use in future clinical studies. The effect of food on PF-06842874 pharmacokinetics may also be evaluated in this study.

Timeline

Start
2019-10-17
Primary completion
2021-07-26
Completion
2021-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-06842874 Small molecule — Oral

Indications

No indication recorded.